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A B S T R A C T
The aim of this retrospective analysis was to evaluate the survival rate in 661 patients with cervical cancer regarding
two time periods 1990–1996 and 1997–2003 and the specific stage related risk factors. The respective five-year survival
was 71.7% and 80.0%. Analyzing the risk factors in the univariate and multivariate regression modalities ultimately
only two parameters, the two time periods and FIGO staging were found to be independent prognostic factors. The ob-
served total improvement in the survival rate of the second time period is followed by an increase in conservative surgery
in stage T1A1, a reduction in the use of adjuvant radiotherapy among operable stages T1b1, T1b2 and T2A, while the
treatment of locally advanced cervical cancer did not differ significantly.
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Introduction
Cervical cancer is the second most common malig-
nancy in women worldwide. Although it has been consid-
ered a preventable cancer because of cervical cytological
screening programs and effective treatment of prein-
vasive lesions, the mortality rate is still high.
In Croatia during last decade the incidence of cervical
cancer was about 16 patients per 100,000 women a year,
reaching an incidence of 13.7 patients per 100,000 wo-
men in 20031.
Risk factors in developing cervical cancer include
young age at first intercourse, multiple sexual partners,
cigarette smoking, high parity and low socioeconomic
status. There is some relationship to oral contraceptives
as risk factors in cervical cancer development with a pos-
sible small increase2. However, infection with the human
papillomavirus (HPV) has been detected in up to 99% of
women with squamous cervical cancer and is defined as
the principal risk factor in cervical cancer development3.
Until recently, major breakthroughs in reducing the
incidence and mortality of cervical cancer have occurred
because of the widely used screening programs. The
Papanicolaou test, known as the Pap test, has been the
most cost- effective cancer-screening test ever developed.
In Rijeka, Croatia, the Pap-test was introduced as a rou-
tine test in gynecologic examination since 19604.
Nevertheless, cervical cancer is still present in our
population and affected patients require diagnosing and
treatment that consists of four steps: establishing the di-
agnosis, defining the extent of the disease, determining
and conducting the optimal treatment and follow-up of
patients for evidence of recurrence and/or treatment re-
lated complications.
The diagnosis of cervical cancer is made exclusively
by histological analysis of a biopsy specimen or by co-
nization. Once histological diagnosis is arrived at, based
on the International Federation of Gynecology and Ob-
stetrics (FIGO) classification, clinical (preoperative) stag-
ing has to be defined. Conization may be part of diagnos-
tic workup, however, its role in definitive treatment will
be discussed later. Diagnostic workup is necessary to de-
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fine preoperative staging using only: physical examina-
tion, colposcopy, cervical or cone biopsy, cystoscopy, lower
gastrointestinal endoscopy or barium enema, intravenous
pyelography and chest radiography. Computed tomogra-
phy (CT) and magnetic resonance (MRI) and positron
emission tomography with computerized tomography
(PET-CT scan) are very useful tools for better definition
of the disease presence, but FIGO is not taken into ac-
count as a staging modality. The treatment strategies for
cervical cancer are related to the diagnosis and the clini-
cal staging system.
The aim of this retrospective analysis was to evaluate
the survival rate regarding two time periods 1990–1996
and 1997–2003 and the specific stage related risk factors.
Subjects and Methods
Medical records of all patients with cervical cancer
primarily treated at the Clinical Hospital Center Rijeka
between 1990 and 2003 were retrospectively reviewed.
The hospital is a tertiary referral center and educational
base of the University of Rijeka, School of Medicine for
the surrounding area of three counties including about
550,000 inhabitants. Six hundred and sixty one patients
with primary cervical cancer were identified.
The prognostic variables investigated for this study
included two time periods, the first from 1990 to 1996,
and the second from 1997 to 2003. December 31, 2006
was the cut off date for patient follow-up
In both time periods we analyzed the following prog-
nostic variables: T stage5, FIGO stage according to the
last revision of cervical cancer staging6 and compared the
5-year survival rate between each subgroup of patients
and the entire group. The stage indicated in this study
referred to pathologic examination after primary surgery
and clinically in cases where radiotherapy or chemo-
irradiation was the first therapeutic option. During the
observed period, cervical cancer treatment was based on
guidelines agreed at the national and hospital level. The
surgical approach was primarily applied to clinical FIGO
stages IA1 to IIA. In stage IIB the primary treatment ap-
proach depended on the clinician. In higher stages radio-
therapy was the treatment of choice. The guidelines on
adjuvant radiotherapy after surgery changed during the
two time periods as well as those on the conservative op-
tion in the treatment of the early stage.
The groups of patient with histology defined as FIGO
Ia1 stage (stromal invasion of not >3.0 mm in depth and
extension of not >7.0 mm) were analyzed separately to
compare the type of treatment and the 5-year survival
rate between the two time periods. Stage IA1 and stage
IA2 cervical cancer were diagnosed either on cone or hys-
terectomy (simple or radical) specimen.
All cone biopsies were bisected and each half was em-
bedded completely and serially processed into 40–90 indi-
vidual sections. The cervices of the extirpated uteri were
treated as a cone and sampled by conventional methods.
Groups of patients with stage disease of IB1 and higher
underwent clinical and instrumental staging. In particu-
lar, stage T1b1, T1b2 and T2a tumor size was assessed by
pelvic examination and under anesthesia at the time of
biopsy or surgery. The definitive tumor dimension in pa-
tients undergoing surgery was determined by measuring
the tumor after uterus removal, while in patients with-
out surgery the definitive dimension was determined
clinically. All patients treated before the last revision of
FIGO staging in 1994 were restaged according to the new
recommendations6.
In the group of patients with pathologic T stages
T1b1, T1b2 and T2a the following categorical variables
were evaluated and compared in the two time periods
(1990–1996 vs. 1997 to 2003): the tumor diameter (less
than 2 cm, 2 to 4 cm, more than 4 cm), age (under 40, 40
to 59, 60 years and over), histology (squamous and ade-
nocarcinoma), tumor differentiation (G1 – well, G2 –
moderate and G3 – poor), T stage, FIGO stage, lymph
node involvement (Nx – not assessed, No – negative
node, N1 – positive node), lymphovascular space involve-
ment (No – Yes) and the mode of treatment (assigned in
each table).
Statistics
Absolute numbers with percentages were used to
show the number of patients per group. The Chi-square
test was used where appropriate. The Kaplan-Meier me-
thod was used to estimate the survival curves. Survival
time was calculated in months from the date of surgery
or therapy beginning at either the date of death, or the
date of last follow-up visit for surviving patients. Uni-
variate analysis of categorical variables was performed
for prognostic significance using the Cox proportional
hazard model and the log-rank test for significance, re-
spectively. Variables with p<0.10 on univariate analysis
were then included in a multivariate Cox proportional
hazard regression analysis. Statistical analyses were per-
formed using MedCalc for Windows, version 9.2.0.2
(MedCalc Software, Mariakerke, Belgium).
Results
The distribution of »T stage« among cervical cancer
patients in the two time periods, the survival in each
stage and the survival per entire group are presented
(Table 1). Staging is the most important predictor of sur-
vival, reflecting the extent of the disease with the risk of
death being higher as a stage increases. Comparing total
survival between the two periods, there is a clear statisti-
cally significant higher 5-year survival rate among pa-
tients treated in the second time period. The group of pa-
tients in T1B1 stage treated in the second period had a
significantly better survival rate than the same staged
patients treated in the first period. However, there was
no difference in patient distribution per stage (Chi-
-square=0.9, p=0.34; not shown). The evaluated patient
age is equal in both time periods (48.7 vs. 48.6 years).
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Distribution of patients in the FIGO stage shows no
difference (Chi-square=14.8, p=0.098; not shown) be-
tween the two time periods (Table 2). The 5-year survival
rate in stages IA1 and IA2 is excellent in both time peri-
ods. Stages IB1, IB2, IIA, IIB and IIIB in the second time
period had better survival rates but without statistical
significance. Nevertheless, a total 5-year survival rate is
significantly higher in the second time period (Table 2).
In our study, FIGO stage IA1 was present in 260
(39.3%) out of 661 patients (Table 3). In the second time
period we found an increase from 37.6% to 40.8% with-
out statistical significance (Chi-square=0.60, p=0.4; not
shown) of patients with stage IA1 (Table 2). The types of
patient treatment in stage IA1 are presented in the Table
3. The distribution of patients regarding the mode of
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TABLE 1
DISTRIBUTION AND SURVIVAL OF CERVICAL CANCER PATIENTS (n=661) ACCORDING TO THE »T« STAGE AND TIME PERIOD
Stage








T1A1 115 (37.6) – 100% 145 (40.8) – 98.4% NS
T1A2 9 (2.9) – 100% 5 (1.4) – 100% NS
T1B1 69 (22.5) – 80.2% 85 (23.9) – 94.2% p=0.017
T1B2 14 (4.6) – 60.9% 25 (7.0) – 77.6% NS
T2A 8 (2.6) – 50.0% 6 (1.7) – 100% NS
T2B 43 (14.1) – 40.8% 26 (7.3) – 53.4% NS
T3A 2 (0.7) – 0.0% 2 (0.6) – 0.0% NS
T3B 43 (14.1) – 21.3% 56 (15.8) – 23.2% NS
T4 3 (1.0) – 0.0% 5 (1.4) – 0.0% NS
Total 306 – 71.7% 355 – 80.0% p=0.02
TABLE 2
DISTRIBUTION AND SURVIVAL OF CERVICAL CANCER PATIENTS (n=661) ACCORDING TO THE FIGO STAGE AND TIME PERIOD
Stage








IA1 115 (37.6) – 100% 145 (40.8) – 98.4% NS
IA2 9 (2.9) – 100% 5 (1.4) – 100% NS
IB1 59 (19.3) – 87.5% 76 (21.4) – 93.5% NS
IB2 13 (4.2) – 66.1% 18 (5.1) – 81.6% NS
IIA 7 (2.3) – 57.1% 6 (1.7) – 100% NS
IIB 36 (11.8) – 43.2% 18 (5.1) – 61.4% NS
IIIA 2 (0.7) – 0.0% 2 (0.6) – 0.0% NS
IIIB 61 (19.9) – 24.8% 74 (20.8) – 40.8% NS
IVA 2 (0.7) – 0.0% 4 (1.1) – 0.0% NS
IVB 2 (0.7) – 0.0% 7 (2.0) – 0.0% NS
Total 306 – 71.7% 355 – 80.0% p=0.02
TABLE 3
TREATMENT OF CERVICAL CANCER PATIENTS






n (%) n (%)
Conisation 54 (47.0%) 84 (58.0%)
Hysterectomy 35 (30.4%) 35 (24.1%)
Hysterectomy &
Lymphadenectomy
23 (20.0%) 16 (11.0%)
Radical hysterectomy
& Lymphadenectomy
*3 (2.6%) 10 (6.9%)
*2 patients treated with adjuvant radiotherapy
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treatment and the time periods shows high significance
(Chi-square=13.87, p=0.008). An increase in conserva-
tive surgical treatment requiring only conization is iden-
tified in 58% of cases in the second time period, while
hysterectomy decreased from 30.4% to 24.1%, also in the
second period. Radical procedures, including lymph node
assessment, mainly due to lymph-vascular space involve-
ment, were present in a similar percent in both observed
periods. The apparent increase in the use of radical hys-
terectomies in the second time period is due to dubious
biopsy material in some patients. However, in the second
time period lymph node staging and/or radical hysterec-
tomy dropped from 22.6% to 17.9% (not shown). During
the first time period two patients received adjuvant pel-
vic irradiation.
»T« stage was used to evaluate the dimension of pri-
mary tumor in women with cervical cancer localized in
the cervix (stage T1b1 and T1b2) and with only vaginal
involvement (T2a), excluding parametrial involvement.
In this group all patients with a concomitant serious
medical condition were not treated or were treated with
palliative radiotherapy. In the medically uncompromised
patients older than 75 years primary treatment included
primary radiotherapy. Patients with primary surgery
were divided into two groups with respect to the use of
adjuvant pelvic irradiation. The indications for adjuvant
pelvic irradiation were changed during the observed
time. The first group of patients consisted of those with
stage from T1B1 to T2A and a dimension of cervical can-
cer less than 2 cm in diameter. The next group of patients
included tumor diameters of 2 to 4 cm and the third
group of patients included tumors of a diameter larger
than 4 cm. Patients staged T2b and T3b were not divided
in the subgroups. Results are presented as a total num-
ber of patients while percents include the proportion of
the entire group within the stage categories (Table 4).
In the group of patients with the tumor diameter less
than 2 cm we observed an obvious inversion in the use of
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TABLE 4
TREATMENT OF CERVICAL CANCER PATIENTS REGARDING T STAGE AND TUMOR DIMENSION
T stage & tumor
dimension
Type of treatment
Period 1990–1996 Period 1997–2003
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adjuvant pelvic irradiation in the second time period
(Chi-square=17.04, p=0.0002; not shown) with a similar
five-year survival rate. In these groups of patients only
one patient with positive pelvic lymph node was identi-
fied in the second time period.
In the group of patients with primary cervical tumor
diameter of 2 to 4 cm an inversion of treatment modali-
ties was identified (Table 4). Namely, the majority of cer-
vical cancer patients in the first time period were treated
with adjuvant pelvic irradiation with a 5-year survival
rate of 69.3%. In the second time period there was a sig-
nificant difference in patients distribution (Chi-square
=20.44, p= 0.0001; not shown), with a decrease in the
use of adjuvant pelvic irradiation after radical surgery
and a total increase of the 5-year survival rate. In the
first time period 10 (23.2%) patients had positive lymph
nodes, while in the second time period positive nodes
were found in 8 patients (20.5%).
In the group of patients with primary cervical tumor
greater than 4 cm primary radiotherapy was applied in
about 11% (Table 4). All patients who underwent surgery
in the first time period were adjunctively treated with
pelvic irradiation. In the second time period one fourth of
patients were treated only with radical surgery. Although
there is no significant change in the modality of treat-
ment in the second time period, the 5-year survival rate
is significantly higher (Chi-square=6.05, p=0.014; not
shown). However, in the second time period a trend of de-
crease in the use of adjuvant radiotherapy was also ob-
served. Analyzing the rate of positive lymph nodes we
identified 10 out of 16 patients (62.5%) in the first time
group and 8 out of 24 (33.3%) patients in second time pe-
riod. The observed difference had no statistical signifi-
cance (Chi-square=2.26, p=0.135; not shown).
In patients with T2B stage in the first time period the
therapy mostly used was radiotherapy (Table 4). In the
second time period radical surgery with adjuvant pelvic
irradiation was encountered in a higher proportion. The
difference of the treatment modality distribution is not
significant. The 5-year survival rate, although higher in
the second time period, did not reach a statistical signifi-
cance.
Clinically staged patients in stage T3B in both time
periods received similar treatment options (Table 4). The
majority of patients were treated with primary radio-
therapy, while only a small number of patients after the
year 2001 received combined chemoirradiation. The rate
of survival in both time period groups was similar.
The patient groups staged T1B1 to T2B and T3B with
177 and 198 patients had a 5-years survival rate of 54.6%
and 68.1% in first and second time period, respectively
(Logrank test p=0.0124; not shown).
Univariate analysis of variables was performed in the
entire group of cervical cancer patients (n= 661). Vari-
ables, two time periods, histology, FIGO stage, degree of
differentiation (G), T stage, lymph node status, type of
treatment and patient age were categorized as shown
(Table 5). All analyzed variables were significant, and
were subsequently included in the multivariate model.
Using Cox proportional hazard regression only two vari-
ables remained significant: two time periods and FIGO
stage (Table 6).
Discussion
The distribution of cervical cancer patients regarding
T stage and FIGO stage are similar during the two ob-
served periods. Approximately 40% of patients with cer-
vical cancer presented with a microinvasive disease lim-
ited to the invasion of 3 mm and 7 mm or less in width.
The diagnosis of stage IA1 cervical cancer has to be es-
tablished at least via cone specimen. Acceptable methods
for diagnostic purposes are cold knife conization and loop
electrosurgical excision. The prognosis is excellent, as
shown in our series. A total 5-year survival for 260 pa-
tients presented with microinvasive cervical cancer in
our analysis is 99.1% (not shown). There is no difference
in the 5-year survival between the two time period groups.
In the last FIGO analysis 829 (7.12%) patients with cer-
vical cancer stage IA1 out of 11639 had a five-year sur-
vival rate of 97.5%7. There are a significantly smaller
proportion of patients with microinvasive cervical cancer
in world statistics compared to our patients (7.12% vs
39.3%). A relative increase in the total number as well as
in the proportion of the entire cervical cancer group
could be attributed firstly to the meticulous analysis of
cervices with multiple serial sections per specimen.
Surgical treatment of patients with cervical cancer
stage IA1 moved to conservative treatment is present in
almost 60%. Hysterectomy is reserved primarily for
women that are past childbearing. Lymphadenectomy is
reserved for those with lymph space involvement, al-
though there is little, if any risk of lymph node metasta-
sis, recurrence and death8–10. Of the 52 patients (not
shown) in our series treated with lymphadenectomy as
part of treatment option firstly due to lymph vascular
space involvement, none had lymph node metastasis.
The 5-year survival rate in our group of patients is
rather high but without statistical significance (99.1% vs
97.5%). In one series with median follow-up of 45 months,
10% of patients developed cervical intraepithelial neopla-
sia 3 – CIN III11. In our series of 126 patients with cervi-
cal cancer stage IA1 treated with a conservative surgical
procedure the cold knife conization and a median fol-
low-up of 72 months, we detected local recurrence in
form of cervical intraepithelial neoplasia irrespective of
their severity in 7 (4%) patients (data not shown).
Squamous lesions are predominantly present in the
early stage of cervical cancer stage IA1, while glandular
lesions are rarely recognized in the early stage. This is
mainly due to difficulties in measuring the glandular le-
sions invasion depth. In our series of 260 patients with
cervical cancer stage IA1 we identified 6 (2.3%) patients
with glandular lesions (data not shown). Currently, the
options of treatment modalities based on retrospective
data include the same procedures with the same indica-
tions as a squamous lesion12,13.
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TABLE 5











Period 1990–1996 (306) 72.0% Reference
1997–2003 (355) 80.0% 5.4 p=0.02 1.46 (1.06–2.02)
Histology Squamous (583) 77.3% Reference
Adeno (78) 65.5% 7.2 p=0.0074 0.57 (0.29–0.83)
FIGO IA1 (260) 99.1% Reference
IA2 (14) 100.0% 0.1 p=0.74 1.01 (0.01–1571)
IB1 (135) 91.0% 17.0 p<0.0001 0.08 (0.03–0.29)
IB2 (31) 74.4% 50.8 p<0.0001 0.03 (0.00–0.003)
IIA (13) 76.9% 38.1 p<0.0001 0.03 (0.00–0.0001)
IIB (54) 46.8% 161.0 p<0.0001 0.01 (0.00–0.003)
IIIA (4) 0.0% 315.0 p<0.0001 0.004 (0.00–0.00001)
IIIB (135) 33.3% 243.0 p<0.0001 0.008 (0.01–0.03)
IVA (6) 0.0% 271.9 p<0.0001 0.005 (0.0000–0.0000)
IVB (9) 0.0% 337.7 p<0.0001 0.005 (0.0000–0.0000)
Gradus G1 (42) 87.5% Reference
G2 (260) 57.8% 10.9 p=0.001 0.25 (0.25–0.70)
G3 (104) 59.5% 9.6 p=0.002 0.26 (0.20–0.69)
Undetermined (255) 99.1% 20.8 p<0.0001 0.06 (0.00–0.05)
T-stage T1A1 (260) 99.1% Reference
T1A2 (14) 100.0% 0.1 p=0.74 –
T1B1 (154) 88.1% 24.8 p<0.0001 0.06 (0.04–0.25)
T1B2 (39) 70.5% 64.9 p<0.0001 0.03 (0.0001–0.004)
T2A (14) 70.7% 54.6 p<0.0001 0.02 (0.0000–0.0000)
T2B (69) 45.2% 180.5 p<0.0001 0.01 (0.001–0.007)
T3A (4) 0.0% 315.9 p<0.0001 0.004 (0.0000–0.0000)
T3B (99) 21.7% 307.5 p<0.0001 0.007 (0.002–0.007)
T4 (8) 0.0% 327.6 p<0.0001 0.005 (0.0000–0.0000)
Lymph Nx (389) 69.9% Reference
node No (224) 92.3% 40.2 p<0.0001 4.6 (2.22–4.52)
status N1 (48) 49.0% 7.0 p=0.008 0.55 (0.27–0.82)
Therapy
Wertheim (W) (85) 94.5% Reference
Without therapy
(21) 0.0% 138.0 p<0.0001 41.5
(1416–2589
7)
Radiotherapy (138) 33.8% 74.0 p<0.0001 20.6 (4.19–9.77)
Conisation (138) 98.4% 2.2 p=0.1 0.3 (0.05–1.5)
Hysterectomy (71) 100.0% 3.5 p=0.06 0.0 (0.02–1.1)
Hysterect. & adj. radiotherapy (7) 68.6% 7.5 p=0.006 7.5 (3.7–2707)
Hysterect. & lymhadenect. (40) 100.0% 2.0 p=0.16 0.0 (0.03–1.79)
Hysterect. & lymhadenect. &
adjuvant radiotherapy (13) 44.0% 34.6 p<0.0001 15.4 (50.8–2573)
Wertheim & adj. radiotherapy (148) 77.3% 11.7 p=0.0006 0.2 (0.16–0.61)
Age < 40 (229) 93.8% Reference
(years) 40–59 (260) 79.2% 21.6 p<0.0001 0.26 (0.19–0.51)
³ 60 (172) 48.1% 111.2 p<0.0001 0.09 (0.07–0.18)
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The patients with cervical cancer stage IA2 are present
in a small percentage (2.9%). The rate (2.4%) of this stage
is similar to that in the last FIGO statistics7. The diagno-
sis of stage IA2 cervical cancer should also be established
via cone biopsy. Although the prognosis for these patients
is also excellent (in our statistics 14 patients had a 5-year
survival rate of 100%, while in previously mentioned sta-
tistics the survival rate in 275 patients was 94.8%) they
are at higher risk for lymph node metastasis and treat-
ment failure. In one series a 6.8% incidence of lymph node
metastasis in patients with cervical cancer stage IA2 is
reported10. Currently, there is a shortage of plausible re-
commendations for the management of cervical cancer in
stage IA2 based on reliable and prospective studies. Until
more data become available pelvic lymph node assessment
is necessary. Hysterectomy could be performed as a simple
procedure, while radical hysterectomy represents surgical
trauma without confirmed survival advantage. In patients
with desired childbearing, large conization with absolute
clear margins and negative lymph node could be the treat-
ment of choice14.
The treatment of choice in cervical cancer stages IB1
to IIA can be influenced by patient age, coexisting medi-
cal conditions and physician bias. Retrospective as well
as prospective studies comparing radical surgery with
pelvic radiation therapy showed similar survival rat-
es15,16. Radical surgery offers few advantages in respect
to preservation of ovaries with fewer detrimental effects
on vaginal function. The advantages of radical surgery
over radiotherapy can be eliminated in patients receiving
postoperative adjuvant radiotherapy. Indication for the
use of adjuvant radiotherapy includes positive lymph
node, positive margins and parametrial involvement.
Other indications for the use of postoperative radiother-
apy in cases without evidence of disease outside the cer-
vix include the presence of high risk factors in the hyster-
ectomy specimen like large tumor diameter, deep cervical
stromal invasion and the invasion of lymph vascular
space involvement17. As tumor diameter increases, the
risk of treatment failure is greater. Tumor diameter
greater than 4 cm leads to the use of various treatment
regimens. The T stage T1B2 includes radical hysterectomy
with pelvic and paraaortic lymphadenectomy followed by
tailored chemoradiation therapy for high-risk patients,
radiation therapy followed by extrafascial hysterectomy,
radiation therapy plus concurrent chemotherapy and
neoadjuvant chemotherapy followed by radical pelvic
surgery18,19. Although some authors recommend the use
of concurrent radiotherapy and chemotherapy as an opti-
mal treatment option19, radical hysterectomy with tai-
lored chemoirradiation for high-risk patients is the most
cost-effective strategy to manage Stage IB2 cervical can-
cer, resulting in a 5-year survival of approximately 70%.
In our series we present only 3 patients treated with pri-
mary radiotherapy, 7 treated with radical hysterectomy
and 17 patients treated with radical hysterectomy and
adjuvant radiotherapy with a total 5-year survival of
87.7%. Radical surgery followed by tailored radiotherapy
is especially suitable in settings where resources are lim-
ited. Adding radiotherapy and chemotherapy in form of
neoadjuvant chemotherapy unnecessarily increases the
total cost without clear advantage in a 5-year survival18.
Comparing the use of adjuvant radiotherapy between
the two time periods in our series we found that in cases
with a tumor diameter less than 2 cm reduction in the
use of radiotherapy did not influence the 5-year survival
rate. In the group of patients with cervical cancer of di-
ameters from 2 to 4 cm the observed reduction in the use
of adjuvant radiotherapy lead to a better 5-year survival.
In the group of patients with cervical cancer stage IB2
(tumor diameter greater than 4 cm) adjuvant radiother-
apy in the second time period was in part reduced with a
higher 5-year survival.
From our results, the philosophy of treatment in the
second time period is one of the significant points in the
treatment acceptance and success measured through a
5-year survival. The lack of this analysis precludes the
precise definition of all elements used in building the in-
dications for adjuvant radiotherapy during the observed
period. Moreover, the indications for adjuvant radiother-
apy after radical surgery changed several times, espe-
cially in the second time period. Conclusively, from the
retrospective results and the results of others20,21 adju-
vant radiotherapy seems to be useful only in the group of
patients with the disease beyond the cervix, i.e., lymph
node metastasis and parametrial involvement.
The standard accepted therapy in the last 15 years for
locally advanced cervical cancer includes radiotherapy
present in the majority of cases in our series. The addi-
tion of cisplatin or a cisplatin containing regimen to a ra-
diation therapy results in better disease control and a
5-year survival22,23. It is part of a standard recommended
therapy. A subsequent meta-analysis of 19 randomized
controlled trials including 4560 patients confirmed the
effectiveness of concurrent chemotherapy and radiation
therapy, which improved the overall survival of patients
with a locally advanced disease24. The new therapeutic
option in patients with locally advanced cervical cancer
promoted by Croatian authors25 seems to produce higher
survival rates, but the preliminary results have to be
confirmed in large multicenter trials.
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TABLE 6










Histology p=0.08 (NS) 1.47 (0.96–2.25)
FIGO p=0.0001 1.5 (1.23–1.83)
Tumor differentiation (G) p=0.21 (NS) 1.2 (0.91–1.57)
Lymph node status p=0.47 (NS) 0.8 (0.41–1.50)
T stage p=0.16 (NS) 1.16 (0.94–1.41)
Therapy p=0.92 (NS) 0.99 (0.85–1.15)
Patients age p=0.47 (NS) 1.11 (0.84–1.46)
Categories of variables as shown in Table 5, NS – non-significant
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In our series of patients in stage T2B or greater even
though the 5-year survival rate is better, the difference
has not reached statistical significance. In stage T2B a
more extensive use of radical surgery with adjuvant ra-
diotherapy and better survival had also no statistical sig-
nificance. A minor number of patients in stage T3B were
treated with the use of chemoirradiation, which was not
taken into account in the actual analysis, and we have
not performed statistical evaluation regarding the appli-
cation of concurrent chemotherapy and radiation ther-
apy in patients with locally advanced cervical cancer.
Conclusions
The comparison of two time periods, 1990–1996 and
1997–2003, showed an overall higher five-year survival
rate in the second time period denoting a significant in-
dependent prognostic parameter. The observed total im-
provement in survival rates was followed by an increase
in conservative surgery in stage T1A1, reducing the ap-
plication of adjuvant radiotherapy in operable stages
T1B1, T1B2 and T2A, while the treatment of locally ad-
vanced cervical cancer has not differed significantly.
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LIJE^ENJE INVAZIVNOG RAKA VRATA MATERNICE: ISKUSTVO RIJEKE
S A @ E T A K
Cilj ovoga retrospektivnog rada uklju~uje analizu pre`ivljavanja u 661 bolesnice s rakom vrata maternice obzirom
na dva razdoblja, 1990–1996 i 1997–2003 kao i specifi~nih ~imbenika rizika obzirom na stadije bolesti. Petogodi{nje
pre`ivljavanje prve skupine iznosilo je 71,7%, dok je u drugoj skupini ono iznosilo 80,0%. Analiziraju}i ~imbenike rizika
u univarijatnoj, te u multivarijatnom regresijskom modelu naposljetku samo dva parametra, vremenska razdoblja i
FIGO stadij imaju nezavisni prognosti~ki zna~aj. Opa`eno bolje pre`ivljavanje u drugom vremenskom razdoblju pra-
}eno je pove}anjem konzervativnih operativnih zahvata u FIGO stadiju IA1, smanjenjem primjene adjuvantne radio-
terapije me|u bolesnicama operabilnog stadija T1b1m T1b2 i T2A, dok se lije~enje lokalno uznapredovanog raka vrata
maternice nije bitno razlikovalo obzirom na vremenska razdoblja.
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